- Home
- DTST vs NRXP Comparison
DTST vs NRXP Comparison
Compare DTST & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTST
- NRXP
- Stock Information
- Founded
- DTST 2001
- NRXP 2015
- Country
- DTST United States
- NRXP United States
- Employees
- DTST N/A
- NRXP N/A
- Industry
- DTST EDP Services
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- DTST Technology
- NRXP Health Care
- Exchange
- DTST Nasdaq
- NRXP Nasdaq
- Market Cap
- DTST 28.2M
- NRXP 32.6M
- IPO Year
- DTST N/A
- NRXP N/A
- Fundamental
- Price
- DTST $3.88
- NRXP $3.27
- Analyst Decision
- DTST
- NRXP Strong Buy
- Analyst Count
- DTST 0
- NRXP 4
- Target Price
- DTST N/A
- NRXP $28.50
- AVG Volume (30 Days)
- DTST 48.0K
- NRXP 402.2K
- Earning Date
- DTST 05-15-2025
- NRXP 05-15-2025
- Dividend Yield
- DTST N/A
- NRXP N/A
- EPS Growth
- DTST N/A
- NRXP N/A
- EPS
- DTST 0.02
- NRXP N/A
- Revenue
- DTST $25,219,312.00
- NRXP N/A
- Revenue This Year
- DTST $12.57
- NRXP N/A
- Revenue Next Year
- DTST $9.29
- NRXP N/A
- P/E Ratio
- DTST $160.15
- NRXP N/A
- Revenue Growth
- DTST N/A
- NRXP N/A
- 52 Week Low
- DTST $2.93
- NRXP $1.10
- 52 Week High
- DTST $6.96
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- DTST 54.72
- NRXP 79.36
- Support Level
- DTST $3.66
- NRXP $2.55
- Resistance Level
- DTST $3.95
- NRXP $2.72
- Average True Range (ATR)
- DTST 0.19
- NRXP 0.25
- MACD
- DTST -0.01
- NRXP 0.05
- Stochastic Oscillator
- DTST 54.90
- NRXP 99.07
About DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.